Strata Skin Sciences, Inc.
SSKN Healthcare Medical Devices
Strata Skin Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.7 million, down 8.54% from fiscal 2024. In the quarter to December 2025, revenue fell 2.97%, EPS grew 111.5%, free cash flow fell 376.9% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SSKN
Strata Skin Sciences, Inc. (SSKN) EV/Sales
As of 15 October 2026, Strata Skin Sciences, Inc. (SSKN) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −6.3× (January 2015) to 4.5× (September 2015); the current reading is higher than 78% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | 61.67% |
| FY2024 | 0.5× | (29.50%) |
| FY2023 | 0.8× | 624.95% |
| FY2022 | 0.1× | 5,447.37% |
| FY2021 | 0.0× | — |
| FY2020 | −0.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | −0.1× | — |
| FY2017 | 0.2× | (68.59%) |
| FY2016 | 0.7× | (30.30%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 0.9× | 54.47% |
| Sep 2025 | 0.6× | (3.84%) |
| Jun 2025 | 0.6× | 4.85% |
| Mar 2025 | 0.6× | 3.81% |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFSA PROFUSA, Inc. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| FEED ENvue Medical, Inc. compare | 0.1× |
| DYNTQ Dynatronics Corporation compare | 0.1× |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| SSKN Strata Skin Sciences, Inc. | 0.7× |
| THMO ThermoGenesis Holdings, Inc. compare | 0.8× |
| AFIB Acutus Medical, Inc. compare | 0.9× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)